Tissue plasminogen activator for the treatment of thromboembolism in infants and children

Maurice Levy, Lee N. Benson, Patricia E. Burrows, Yedidia Bentur, Dawn K. Strong, Joanne Smith, David Johnson, Sheila Jacobson, Gideon Koren

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


We report our experience with the use of tissue plasminogen activator to treat 12 infants and children with various thromboembolic states after conventional thrombolytic agents had failed. The dosage range was between 0.1 to 0.5 mg/kg per hour. Complete clot dissolution occurred in seven cases after 2 hours to 3 days of therapy. Partial clot dissolution and clinical improvement were noted in another four patients. Bleeding complications were noted in 6 of the 12 patients and included bruising, oozing from various venipuncture sites, and bleeding; these complications were controlled by clinically available means. In all cases with bleeding the dose rate was in the higher range (0.46 to 0.50 mg/kg per hour). In one patient, restlessness, agitation, and screaming were noted during administration of tissue plasminogen activator and when it was reinstituted. We conclude that tissue plasminogen activator is effective in inducing clot lysis in children. Because the effective dose appears to overlap with those causing bleeding, we recommend that a dose of 0.1 mg/kg per hour be started and increased gradually if clot dissolution does not occur, with close monitoring for bleeding.

Original languageEnglish
Pages (from-to)467-472
Number of pages6
JournalJournal of Pediatrics
Issue number3
StatePublished - Mar 1991
Externally publishedYes


Dive into the research topics of 'Tissue plasminogen activator for the treatment of thromboembolism in infants and children'. Together they form a unique fingerprint.

Cite this